HOUSE BILL No. 2709

By Committee on Agriculture

2-14

AN ACT concerning controlled substances; relating to cannabis; removing certain products that contain a delta-9 tetrahydrocannabinol concentration of up to 0.3% on a dry weight basis from the list of controlled substances listed in schedule I of the uniform controlled substances act; amending K.S.A. 2019 Supp. 21-5701, 65-4101 and 65-4105 and repealing the existing sections.

Be it enacted by the Legislature of the State of Kansas:

Section 1. K.S.A. 2019 Supp. 21-5701 is hereby amended to read as follows: 21-5701. As used in K.S.A. 2019 Supp. 21-5701 through 21-5717, and amendments thereto: (a) "Controlled substance" means any drug, substance or immediate precursor included in any of the schedules designated in K.S.A. 65-4105, 65-4107, 65-4109, 65-4111 and 65-4113, and amendments thereto.

- (b) (1) "Controlled substance analog" means a substance that is intended for human consumption, and at least one of the following:
- (A) The chemical structure of the substance is substantially similar to the chemical structure of a controlled substance listed in or added to the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto;
- (B) the substance has a stimulant, depressant or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant or hallucinogenic effect on the central nervous system of a controlled substance included in the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto; or
- (C) with respect to a particular individual, such individual represents or intends the substance to have a stimulant, depressant or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant or hallucinogenic effect on the central nervous system of a controlled substance included in the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto.
 - (2) "Controlled substance analog" does not include:
 - (A) A controlled substance:
- (B) a substance for which there is an approved new drug application; or
 - (C) a substance with respect to which an exemption is in effect for

investigational use by a particular person under section 505 of the federal food, drug, and cosmetic act, 21 U.S.C. § 355, to the extent conduct with respect to the substance is permitted by the exemption.

- (c) "Cultivate" means the planting or promotion of growth of five or more plants that contain or can produce controlled substances.
- (d) "Distribute" means the actual, constructive or attempted transfer from one person to another of some item whether or not there is an agency relationship. "Distribute" includes, but is not limited to, sale, offer for sale or any act that causes some item to be transferred from one person to another. "Distribute" does not include acts of administering, dispensing or prescribing a controlled substance as authorized by the pharmacy act of the state of Kansas, the uniform controlled substances act or otherwise authorized by law.
 - (e) "Drug" means:
- (1) Substances recognized as drugs in the official United States pharmacopeia, official homeopathic pharmacopoeia of the United States or official national formulary or any supplement to any of them;
- (2) substances intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in humans or animals;
- (3) substances, other than food, intended to affect the structure or any function of the body of humans or animals; and
- (4) substances intended for use as a component of any article specified in paragraph (1), (2) or (3). It does not include devices or their components, parts or accessories.
- (f) "Drug paraphernalia" means all equipment and materials of any kind that are used, or primarily intended or designed for use in planting, propagating, cultivating, growing, harvesting, manufacturing, compounding, converting, producing, processing, preparing, testing, analyzing, packaging, repackaging, storing, containing, concealing, injecting, ingesting, inhaling or otherwise introducing into the human body a controlled substance and in violation of this act. "Drug paraphernalia" shall include, but is not limited to:
- (1) Kits used or intended for use in planting, propagating, cultivating, growing or harvesting any species of plant that is a controlled substance or from which a controlled substance can be derived;
- (2) kits used or intended for use in manufacturing, compounding, converting, producing, processing or preparing controlled substances;
- (3) isomerization devices used or intended for use in increasing the potency of any species of plant that is a controlled substance;
- (4) testing equipment used or intended for use in identifying or in analyzing the strength, effectiveness or purity of controlled substances;
- (5) scales and balances used or intended for use in weighing or measuring controlled substances;

1

2

3

4

5

6 7

8

9

10

11

12

13 14

15

16

17

18

19 20

21

22

23

24

25

26

27

28

29 30

31

32

33

34

35 36

38

41

(6) diluents and adulterants, including, but not limited to, quinine hydrochloride, mannitol, mannite, dextrose and lactose that are used or intended for use in cutting controlled substances;

- (7) separation gins and sifters used or intended for use in removing twigs and seeds from or otherwise cleaning or refining marijuana;
- (8) blenders, bowls, containers, spoons and mixing devices used or intended for use in compounding controlled substances;
- (9) capsules, balloons, envelopes, bags and other containers used or intended for use in packaging small quantities of controlled substances;
- (10) containers and other objects used or intended for use in storing or concealing controlled substances;
- (11) hypodermic syringes, needles and other objects used or intended for use in parenterally injecting controlled substances into the human body;
- (12) objects used or primarily intended or designed for use in ingesting, inhaling or otherwise introducing marijuana, cocaine, hashish, hashish oil, phencyclidine (PCP), methamphetamine or amphetamine into the human body, such as:
- (A) Metal, wooden, acrylic, glass, stone, plastic or ceramic pipes with or without screens, permanent screens, hashish heads or punctured metal bowls;
- (B) water pipes, bongs or smoking pipes designed to draw smoke through water or another cooling device;
- (C) carburetion pipes, glass or other heat resistant tubes or any other device used, intended to be used or designed to be used to cause vaporization of a controlled substance for inhalation;
 - (D) smoking and carburetion masks;
- (E) roach clips, objects used to hold burning material, such as a marijuana cigarette, that has become too small or too short to be held in the hand;
 - (F) miniature cocaine spoons and cocaine vials;
 - (G) chamber smoking pipes;
 - (H) carburetor smoking pipes;
 - (I) electric smoking pipes;
- (J) air-driven smoking pipes:
 - (K) chillums;
- 37 (L) bongs;
 - (M) ice pipes or chillers;
- 39 (N) any smoking pipe manufactured to disguise its intended purpose;
- 40 (O) wired cigarette papers; or
 - (P) cocaine freebase kits.
- "Drug paraphernalia" shall not include any products, chemicals or materials described in K.S.A. 2019 Supp. 21-5709(a), and amendments

thereto.

- (g) "Immediate precursor" means a substance that the state board of pharmacy has found to be and by rules and regulations designates as being the principal compound commonly used or produced primarily for use and that is an immediate chemical intermediary used or likely to be used in the manufacture of a controlled substance, the control of which is necessary to prevent, curtail or limit manufacture.
 - (h) "Isomer" means all enantiomers and diastereomers.
- (i) "Manufacture" means the production, preparation, propagation, compounding, conversion or processing of a controlled substance either directly or indirectly or by extraction from substances of natural origin or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis. "Manufacture" does not include:
- (1) The preparation or compounding of a controlled substance by an individual for the individual's own lawful use or the preparation, compounding, packaging or labeling of a controlled substance:
- (A) By a practitioner or the practitioner's agent pursuant to a lawful order of a practitioner as an incident to the practitioner's administering or dispensing of a controlled substance in the course of the practitioner's professional practice; or
- (B) by a practitioner or by the practitioner's authorized agent under such practitioner's supervision for the purpose of or as an incident to research, teaching or chemical analysis or by a pharmacist or medical care facility as an incident to dispensing of a controlled substance; or
- (2) the addition of diluents or adulterants, including, but not limited to, quinine hydrochloride, mannitol, mannite, dextrose or lactose that are intended for use in cutting a controlled substance.
- "Marijuana" means any of the following that contains a delta-9 tetrahydrocannabinol concentration that exceeds 0.3% on a dry weight basis: All parts of all varieties of the plant Cannabis whether growing or not, the seeds thereof, the resin extracted from any part of the plant and every compound, manufacture, salt, derivative, mixture or preparation of the plant, its or of the seeds or resin of the plant. "Marijuana" does not include: (1) The mature stalks of the plant, fiber produced from the stalks, oil or eake made from the seeds of the plant, any other compound, manufacture, salt, derivative, mixture or preparation of the mature stalks, except the resin extracted therefrom, fiber, oil or cake or the sterilized seed of the plant that is incapable of germination; (2) any substance listed inschedules II through V of the uniform controlled substances act; (3)eannabidiol (other trade name: 2-[(3-methyl-6-(1-methylethenyl)-2eyelohexen-1-yl]-5-pentyl-1,3-benzenediol); or (4) industrial hemp asdefined in K.S.A. 2019 Supp. 2-3901, and amendments thereto, wheneultivated, produced, possessed or used for activities authorized by the

eommercial industrial hemp act any of the following that contains a delta-9 tetrahydrocannabinol concentration of not more than 0.3% on a dry weight basis: All parts of all varieties of the plant Cannabis whether growing or not, the seeds thereof, the resin extracted from any part of the plant and every compound, manufacture, salt, derivative, mixture or preparation of the plant or of the seeds or resin of the plant.

- (k) "Minor" means a person under 18 years of age.
- (l) "Narcotic drug" means any of the following whether produced directly or indirectly by extraction from substances of vegetable origin or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis:
- (1) Opium and opiate and any salt, compound, derivative or preparation of opium or opiate;
- (2) any salt, compound, isomer, derivative or preparation thereof that is chemically equivalent or identical with any of the substances referred to in paragraph (1) but not including the isoquinoline alkaloids of opium;
 - (3) opium poppy and poppy straw;
- (4) coca leaves and any salt, compound, derivative or preparation of coca leaves and any salt, compound, isomer, derivative or preparation thereof that is chemically equivalent or identical with any of these substances, but not including decocainized coca leaves or extractions of coca leaves that do not contain cocaine or ecgonine.
- (m) "Opiate" means any substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having addiction-forming or addiction-sustaining liability. "Opiate" does not include, unless specifically designated as controlled under K.S.A. 65-4102, and amendments thereto, the dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its salts (dextromethorphan). "Opiate" does include its racemic and levorotatory forms.
- (n) "Opium poppy" means the plant of the species Papaver somniferum l. except its seeds.
- (o) "Person" means an individual, corporation, government or governmental subdivision or agency, business trust, estate, trust, partnership, association or any other legal entity.
- (p) "Poppy straw" means all parts, except the seeds, of the opium poppy, after mowing.
- (q) "Possession" means having joint or exclusive control over an item with knowledge of and intent to have such control or knowingly keeping some item in a place where the person has some measure of access and right of control.
- (r) "School property" means property upon which is located a structure used by a unified school district or an accredited nonpublic

school for student instruction or attendance or extracurricular activities of pupils enrolled in kindergarten or any of the grades one through 12. This definition shall not be construed as requiring that school be in session or that classes are actually being held at the time of the offense or that children must be present within the structure or on the property during the time of any alleged criminal act. If the structure or property meets the above definition, the actual use of that structure or property at the time alleged shall not be a defense to the crime charged or the sentence imposed.

- (s) "Simulated controlled substance" means any product that identifies itself by a common name or slang term associated with a controlled substance and that indicates on its label or accompanying promotional material that the product simulates the effect of a controlled substance.
- Sec. 2. K.S.A. 2019 Supp. 65-4101 is hereby amended to read as follows: 65-4101. As used in this act: (a) "Administer" means the direct application of a controlled substance, whether by injection, inhalation, ingestion or any other means, to the body of a patient or research subject by:
- (1) A practitioner or pursuant to the lawful direction of a practitioner; or
- (2) the patient or research subject at the direction and in the presence of the practitioner.
- (b) "Agent" means an authorized person who acts on behalf of or at the direction of a manufacturer, distributor or dispenser. It does not include a common carrier, public warehouseman or employee of the carrier or warehouseman
- (c) "Application service provider" means an entity that sells electronic prescription or pharmacy prescription applications as a hosted service where the entity controls access to the application and maintains the software and records on its server.
 - (d) "Board" means the state board of pharmacy.
- (e) "Bureau" means the bureau of narcotics and dangerous drugs, United States department of justice, or its successor agency.
- (f) "Controlled substance" means any drug, substance or immediate precursor included in any of the schedules designated in K.S.A. 65-4105, 65-4107, 65-4109, 65-4111 and 65-4113, and amendments thereto.
- (g) (1) "Controlled substance analog" means a substance that is intended for human consumption, and at least one of the following:
- (A) The chemical structure of the substance is substantially similar to the chemical structure of a controlled substance listed in or added to the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto;

(B) the substance has a stimulant, depressant or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant or hallucinogenic effect on the central nervous system of a controlled substance included in the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto; or

- (C) with respect to a particular individual, such individual represents or intends the substance to have a stimulant, depressant or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant or hallucinogenic effect on the central nervous system of a controlled substance included in the schedules designated in K.S.A. 65-4105 or 65-4107, and amendments thereto.
 - (2) "Controlled substance analog" does not include:
 - (A) A controlled substance;
- (B) a substance for which there is an approved new drug application; or
- (C) a substance with respect to which an exemption is in effect for investigational use by a particular person under section 505 of the federal food, drug and cosmetic act, 21 U.S.C. § 355, to the extent conduct with respect to the substance is permitted by the exemption.
- (h) "Counterfeit substance" means a controlled substance that, or the container or labeling of which, without authorization bears the trademark, trade name or other identifying mark, imprint, number or device or any likeness thereof of a manufacturer, distributor or dispenser other than the person who in fact manufactured, distributed or dispensed the substance.
- (i) "Cultivate" means the planting or promotion of growth of five or more plants that contain or can produce controlled substances.
- (j) "DEA" means the U.S. department of justice, drug enforcement administration.
- (k) "Deliver" or "delivery" means the actual, constructive or attempted transfer from one person to another of a controlled substance, whether or not there is an agency relationship.
- (l) "Dispense" means to deliver a controlled substance to an ultimate user or research subject by or pursuant to the lawful order of a practitioner, including the packaging, labeling or compounding necessary to prepare the substance for that delivery, or pursuant to the prescription of a mid-level practitioner.
- (m) "Dispenser" means a practitioner or pharmacist who dispenses, or a physician assistant who has authority to dispense prescription-only drugs in accordance with K.S.A. 65-28a08(b), and amendments thereto.
- (n) "Distribute" means to deliver other than by administering or dispensing a controlled substance.
 - (o) "Distributor" means a person who distributes.
 - (p) "Drug" means: (1) Substances recognized as drugs in the official

United States pharmacopeia, official homeopathic pharmacopoeia of the United States or official national formulary or any supplement to any of them; (2) substances intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in human or animals; (3) substances (other than food) intended to affect the structure or any function of the body of human or animals; and (4) substances intended for use as a component of any article specified in paragraph (1), (2) or (3). It does not include devices or their components, parts or accessories.

- (q) "Immediate precursor" means a substance that the board has found to be and by rule and regulation designates as being the principal compound commonly used or produced primarily for use and that is an immediate chemical intermediary used or likely to be used in the manufacture of a controlled substance, the control of which is necessary to prevent, curtail or limit manufacture.
- (r) "Electronic prescription" means an electronically prepared prescription that is authorized and transmitted from the prescriber to the pharmacy by means of electronic transmission.
- (s) "Electronic prescription application" means software that is used to create electronic prescriptions and that is intended to be installed on the prescriber's computers and servers where access and records are controlled by the prescriber.
- (t) "Electronic signature" means a confidential personalized digital key, code, number or other method for secure electronic data transmissions that identifies a particular person as the source of the message, authenticates the signatory of the message and indicates the person's approval of the information contained in the transmission.
- (u) "Electronic transmission" means the transmission of an electronic prescription, formatted as an electronic data file, from a prescriber's electronic prescription application to a pharmacy's computer, where the data file is imported into the pharmacy prescription application.
- (v) "Electronically prepared prescription" means a prescription that is generated using an electronic prescription application.
- (w) "Facsimile transmission" or "fax transmission" means the transmission of a digital image of a prescription from the prescriber or the prescriber's agent to the pharmacy. "Facsimile transmission" includes, but is not limited to, transmission of a written prescription between the prescriber's fax machine and the pharmacy's fax machine; transmission of an electronically prepared prescription from the prescriber's electronic prescription application to the pharmacy's fax machine, computer or printer; or transmission of an electronically prepared prescription from the prescriber's fax machine to the pharmacy's fax machine, computer or printer.
 - (x) "Intermediary" means any technology system that receives and

1 2

3

4

5

6

7

8

9

10

11 12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31 32

33

34 35

36 37

38

39

40 41

42

43

transmits an electronic prescription between the prescriber and the pharmacy.

- (y) "Isomer" means all enantiomers and diastereomers.
- (z) "Manufacture" means the production, preparation, propagation, compounding, conversion or processing of a controlled substance either directly or indirectly or by extraction from substances of natural origin or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis and includes any packaging or repackaging of the substance or labeling or relabeling of its container, except that this term does not include the preparation or compounding of a controlled substance by an individual for the individual's own lawful use or the preparation, compounding, packaging or labeling of a controlled substance:
- (1) By a practitioner or the practitioner's agent pursuant to a lawful order of a practitioner as an incident to the practitioner's administering or dispensing of a controlled substance in the course of the practitioner's professional practice; or
- (2) by a practitioner or by the practitioner's authorized agent under such practitioner's supervision for the purpose of or as an incident to research, teaching or chemical analysis or by a pharmacist or medical care facility as an incident to dispensing of a controlled substance.
- (aa) "Marijuana" means any of the following that contains a delta-9 tetrahydrocannabinol concentration that exceeds 0.3% on a dry weight basis: All parts of all varieties of the plant Cannabis whether growing or not, the seeds thereof, the resin extracted from any part of the plant and every compound, manufacture, salt, derivative, mixture or preparation of the plant, its or of the seeds or resin of the plant. It "Marijuana" does not include: (1) The mature stalks of the plant, fiber produced from the stalks. oil or eake made from the seeds of the plant, any other compound, manufacture, salt, derivative, mixture or preparation of the mature stalks, except the resin extracted therefrom, fiber, oil or cake or the sterilized seed of the plant that is incapable of germination; (2) any substance listed inschedules II through V of the uniform controlled substances act; (3)eannabidiol (other trade name: 2-[(3-methyl-6-(1-methylethenyl)-2eyelohexen-1-yl]-5-pentyl-1,3-benzenediol); or (4) industrial hemp as defined in K.S.A. 2019 Supp. 2-3901, and amendments thereto, wheneultivated, produced, possessed or used for activities authorized by the commercial industrial hemp act any of the following that contains a delta-9 tetrahydrocannabinol concentration of not more than 0.3% on a dry weight basis: All parts of all varieties of the plant Cannabis whether growing or not, the seeds thereof, the resin extracted from any part of the plant and every compound, manufacture, salt, derivative, mixture or preparation of the plant or of the seeds or resin of the plant.

 (bb) "Medical care facility" shall have the meaning ascribed to that term in K.S.A. 65-425, and amendments thereto.

- (cc) "Mid-level practitioner" means a certified nurse-midwife engaging in the independent practice of midwifery under the independent practice of midwifery act, an advanced practice registered nurse issued a license pursuant to K.S.A. 65-1131, and amendments thereto, who has authority to prescribe drugs pursuant to a written protocol with a responsible physician under K.S.A. 65-1130, and amendments thereto, or a physician assistant licensed under the physician assistant licensure act who has authority to prescribe drugs pursuant to a written agreement with a supervising physician under K.S.A. 65-28a08, and amendments thereto.
- (dd) "Narcotic drug" means any of the following whether produced directly or indirectly by extraction from substances of vegetable origin or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis:
- (1) Opium and opiate and any salt, compound, derivative or preparation of opium or opiate;
- (2) any salt, compound, isomer, derivative or preparation thereof that is chemically equivalent or identical with any of the substances referred to in paragraph (1) but not including the isoquinoline alkaloids of opium;
 - (3) opium poppy and poppy straw;
- (4) coca leaves and any salt, compound, derivative or preparation of coca leaves, and any salt, compound, isomer, derivative or preparation thereof that is chemically equivalent or identical with any of these substances, but not including decocainized coca leaves or extractions of coca leaves that do not contain cocaine or ecgonine.
- (ee) "Opiate" means any substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having addiction-forming or addiction-sustaining liability. It does not include, unless specifically designated as controlled under K.S.A. 65-4102, and amendments thereto, the dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its salts (dextromethorphan). It does include its racemic and levorotatory forms.
- (ff) "Opium poppy" means the plant of the species Papaver somniferum l. except its seeds.
- (gg) "Person" means an individual, corporation, government, or governmental subdivision or agency, business trust, estate, trust, partnership or association or any other legal entity.
- (hh) "Pharmacist" means any natural person licensed under K.S.A. 65-1625 et seq., and amendments thereto, to practice pharmacy.
- (ii) "Pharmacist intern" means: (1) A student currently enrolled in an accredited pharmacy program; (2) a graduate of an accredited pharmacy program serving such person's internship; or (3) a graduate of a pharmacy

1 2

program located outside of the United States that is not accredited and who had successfully passed equivalency examinations approved by the board.

- (jj) "Pharmacy prescription application" means software that is used to process prescription information, is installed on a pharmacy's computers and servers, and is controlled by the pharmacy.
- (kk) "Poppy straw" means all parts, except the seeds, of the opium poppy, after mowing.
- (II) "Practitioner" means a person licensed to practice medicine and surgery, dentist, podiatrist, veterinarian, optometrist, or scientific investigator or other person authorized by law to use a controlled substance in teaching or chemical analysis or to conduct research with respect to a controlled substance.
 - (mm) "Prescriber" means a practitioner or a mid-level practitioner.
- (nn) "Production" includes the manufacture, planting, cultivation, growing or harvesting of a controlled substance.
- (00) "Readily retrievable" means that records kept by automatic data processing applications or other electronic or mechanized recordkeeping systems can be separated out from all other records within a reasonable time not to exceed 48 hours of a request from the board or other authorized agent or that hard-copy records are kept on which certain items are asterisked, redlined or in some other manner visually identifiable apart from other items appearing on the records.
- (pp) "Ultimate user" means a person who lawfully possesses a controlled substance for such person's own use or for the use of a member of such person's household or for administering to an animal owned by such person or by a member of such person's household.
- Sec. 3. K.S.A. 2019 Supp. 65-4105 is hereby amended to read as follows: 65-4105. (a) The controlled substances listed in this section are included in schedule I and the number set forth opposite each drug or substance is the DEA controlled substances code that has been assigned to it
- (b) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:
- 36 (1) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-Nphenylacetamide)......9821
- 38 (2) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide).......9815
- 40 (3) Acetylmethadol......9601
- 41 (4) Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide; 42 acryloylfentanyl).......9811
 - (5) AH-7921 (3,4-dichloro-N-[(1-

2 (6) Allylprodine	9551
4 (except levo-alphacetylmethadol also known as levo-alpha- 5 acetylmethadol, levomethadyl acetate or LAAM) 6 (8) Alphameprodine	9602
acetylmethadol, levomethadyl acetate or LAAM) (8) Alphameprodine	9603
6 (8) Alphameprodine	
6 (8) Alphameprodine	
7 (9) Alphamethadol	9604
8 (10) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl- 9 piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N- 10 propanilido) piperidine)	
piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine)	
propanilido) piperidine)	
 (11) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide)	9814
12 piperidinyl]-N-phenylpropanamide)	
 (12) Benzethidine	9832
 (13) Betacetylmethadol	
15 (14) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piper N-phenylpropanamide)	
16 N-phenylpropanamide)	
17 (15) Beta-hydroxy-3-methylfentanyl (other name: N-[1-(2-hydroxy	
phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide)	
19 (16) Beta-hydroxythiofentanyl (N-[1-[2-hydroxy-2-(thiophen-2-	
yl)ethyl]piperidin-4-yl]-N-phenylpropionamide)	9836
21 (17) Betameprodine	
22 (18) Betamethadol	
23 (19) Betaprodine	9611
24 (20) Butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-	
phenylbutyramide)	9822
26 (21) Clonitazene	
27 (22) Cyclopentyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-	
28 phenylcyclopentanecarboxamide)	
29 (23) Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-	
phenylcyclopropanecarboxamide)	9845
31 (24) Dextromoramide	
32 (25) Diampromide	9615
33 (26) Diethylthiambutene	
34 (27) Difenoxin	
35 (28) Dimenoxadol	
36 (29) Dimepheptanol	
37 (30) Dimethylthiambutene	
38 (31) Dioxaphetyl butyrate	
39 (32) Dipipanone	
40 (33) Ethylmethylthiambutene	
41 (34) Etonitazene	
42 (35) Etoxeridine	
43 (36) Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfura	

1		carboxamide)	9834
2	(37)	Furethidine	9626
3	(38)	Hydroxypethidine	9627
4	(39)	Isobutyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-	
5		phenylisobutyramide)	
6	(40)	Ketobemidone	9628
7		Levomoramide	
8		Levophenacylmorphan	
9	(43)	Methoxyacetyl fentanyl (2-methoxy-N-(1-phenethylpiperidin-4-y	
10		N-phenylacetamide)	9825
11	(44)	3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N	Į-
12		phenylpropanamide)	9813
13	(45)	3-Methylthiofentanyl (N-[(3-methyl-1-(2-thienyl)ethyl-4-	
14		piperidinyl]-N-phenylpropanamide)	
15		Morpheridine	
16	(47)	Ocfentanil (N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperi	din-
17		4-yl)acetamide)	
18	(48)	O-desmethyltramadol	
19		Some trade or other names: 2-((dimethylamino)methyl-1-(3-	
20		hydroxyphenyl)cyclohexanol;3-(2-((dimethylamino)methyl)-1-	
21		hydroxycyclohexyl)phenol	
22		MPPP (1-methyl-4-phenyl-4-propionoxypiperidine)	9661
23		MT-45 (1-cychohexyl-4-(1,2-diphenylethyl)piperazine)	
24		Noracymethadol	
25		Norlevorphanol	
26		Normethadone	
27	(54)	Norpipanone	
28	(55)	Ortho-fluorofentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperid	
29		4-yl)propionamide; 2-fluorofentanyl)	9816
30	(56)	Para-chloroisobutyryl fentanyl (N-(4-chlorophenyl)-N-(1-	
31		phenethylpiperidin-4-yl)isobutyramide)	
32	(57)	Para-fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-	
33		phenethylpiperidin-4-yl)butyramide)	
34	(58)	Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-	
35	(= 0)	piperidinyl]propanamide)	9812
36	(59)	Para-fluoroisobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-	
37		phenethylpiperidin-4-yl)isobutyramide,	
38	((0)	4-fluoroisobutyryl fentanyl)	9824
39	(60)	Para-methoxybutyryl fentanyl (N-(4-methoxyphenyl)-N-(1-	
40	(61)	phenethylpiperidin-4-yl)butyramide)	0.666
41	(61)	PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine)	9663
42		Phenadoxone	
43	(63)	Phenampromide.	9638

1	(64)	Phenomorphan	9647
2		Phenoperidine	
3	(66)	Piritramide	9642
4	(67)	Proheptazine	9643
5		Properidine	
6		Propiram	
7	(70)	Racemoramide	9645
8	(71)	Tetrahydrofuranyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-	
9	, ,	phenyltetrahydrofuran-2-carboxamide)	9843
10	(72)	Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-	
11	` /	propanamide)	9835
12	(73)	Tilidine	
13	(74)	Trimeperidine	9646
14	(75)	U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-	
15	, ,	methylbenzamide)	9547
16	(76)	Valeryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-	
17		phenylpentanamide)	
18	(0	e) Any of the following opium derivatives, their salts, isome	ers and
19		of isomers, unless specifically excepted, whenever the existe	
20	these	e salts, isomers and salts of isomers is possible within the s	pecific
21	chen	nical designation:	
22	(1)	Acetorphine	9319
23	(2)	Acetyldihydrocodeine	
24	(3)	Benzylmorphine	
25	(4)	Codeine methylbromide	
26	(5)	Codeine-N-Oxide	
27	(6)	Cyprenorphine	9054
28	(7)	Desomorphine	
29	(8)	Dihydromorphine	9145
30	(9)	Drotebanol	
31	(10)	Etorphine (except hydrochloride salt)	
32	(11)	Heroin	
33		Hydromorphinol	
34	(13)	Methyldesorphine	
35	(14)	Methyldihydromorphine	
36		Morphine methylbromide	
37		Morphine methylsulfonate	
38	(17)	•	
39	(18)		
40		Nicocodeine	
11		Nicomorphine	
12		Normorphine	
13	(22)	Pholcodine	9314

1	(23)	Thebacon
2	(0	Any material, compound, mixture or preparation that contains any
3	quan	tity of the following hallucinogenic substances, their salts, isomers
4	and s	salts of isomers, unless specifically excepted, whenever the existence
5	of th	ese salts, isomers and salts of isomers is possible within the specific
6	chen	nical designation:
7	(1)	Alpha-ethyltryptamine 7249 Some trade or other names:
8	` /	etryptamine; Monase; α-ethyl-1H-indole-3-ethanamine; 3-(2-
9		aminobutyl) indole; α-ET; and AET.
10	(2)	4-bromo-2,5-dimethoxy-amphetamine
11	()	Some trade or other names: 4-bromo-2,5-dimethoxy-alpha-
12		methylphenethylamine; 4-bromo-2,5-DMA.
13	(3)	2,5-dimethoxyamphetamine
14	(-)	Some trade or other names: 2,5-dimethoxy-alpha-methyl-
15		phenethylamine; 2,5-DMA.
16	(4)	4-methoxyamphetamine
17	(.)	Some trade or other names: 4-methoxy-alpha-methylphene-
18		thylamine; paramethoxyamphetamine; PMA.
19	(5)	5-methoxy-3,4-methylenedioxy-amphetamine
20	(6)	4-methyl-2,5-dimethoxy-amphetamine
21	(0)	Some trade or other names: 4-methyl-2,5-dimethoxy-alpha-
22		mathylphanathylamina: "DOM": and "STD"
23	(7)	3,4-methylenedioxy amphetamine
24	(8)	3,4-methylenedioxymethamphetamine (MDMA)
25	(9)	3,4-methylenedioxy-N-ethylamphetamine (also known as N-ethyl-
26	(-)	alpha-methyl-3,4 (methylenedioxy) phenethylamine, N-ethyl MDA,
27		MDE, and MDEA)
28	(10)	N-hydroxy-3,4-methylenedioxyamphetamine (also known as N-
29	()	hydroxy-alpha-methyl-3,4-(methylenedioxy) phenethylamine, and
30		N-hydroxy MDA)
31	(11)	3,4,5-trimethoxy amphetamine
32		Bufotenine
33	(1-)	Some trade or other names: 3-(Beta-Dimethylaminoethyl)-5-
34		hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N, N-
35		dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine.
36	(13)	Diethyltryptamine
37	(13)	Some trade or other names: N,N-Diethyltryptamine; DET.
38	(14)	Dimethyltryptamine
39	(11)	Some trade or other names: DMT.
40	(15)	Ibogaine
41	(15)	Some trade or other names: 7-Ethyl-6,6 Beta,7,8,9,10,12,13-
42		octahydro-2-methoxy-6,9-methano-5H-pyrido[1',2':1,2]azepino[5,4-
43		b]indole; Tabernanthe iboga
		ojinaoie, iuoeinanine 100gu

1	(16)	Lysergic acid diethylamide73	15
2	(17)	Marijuana736	50
3	(18)	Mescaline	31
4	(19)	Parahexyl733	74
5	` /	Some trade or other names: 3-Hexyl-l-hydroxy-7,8,9,10-tetrahydro-	-
6		6,6,9-trimethyl-6H-dibenzo[b,d]pyran; Synhexyl.	
7	(20)	Peyote74	15
8	` /	Meaning all parts of the plant presently classified botanically as	
9		Lophophora williamsii Lemaire, whether growing or not, the seeds	
10		thereof, any extract from any part of such plant, and every	
11		compound, manufacture, salts, derivative, mixture or preparation of	•
12		such plant, its seeds or extracts.	
13	(21)	N-ethyl-3-piperidyl benzilate748	32
14	(22)	N-methyl-3-piperidyl benzilate	
15		Psilocybin742	
16		Psilocyn	
17	()	Some trade or other names: Psilocin.	
18	(25)	Ethylamine analog of phencyclidine	55
19	(==)	Some trade or other names: N-ethyl-1-phenyl-cyclo-hexylamine; (1	
20		phenylcyclohexyl)ethylamine; N-(1-phenylcyclohexyl)ethylamine;	
21		cyclohexamine; PCE.	
22	(26)	Pyrrolidine analog of phencyclidine745	58
23	()	Some trade or other names: 1-(1-phenylcyclohexyl)-pyrrolidine;	
24		PCPy; PHP.	
25	(27)	Thiophene analog of phencyclidine743	70
26	(')	Some trade or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine	
27		2-thienyl analog of phencyclidine; TPCP; TCP.	,
28	(28)	1-[1-(2-thienyl)-cyclohexyl] pyrrolidine74	73
29		Some other names: TCPv.	
30	(29)	2,5-dimethoxy-4-ethylamphetamine739	99
31	(-)	Some trade or other names: DOET.	
32	(30)	Salvia divinorum or salvinorum A; all parts of the plant presently	
33	()	classified botanically as salvia divinorum, whether growing or not,	
34		the seeds thereof, any extract from any part of such plant, and every	,
35		compound, manufacture, salts, derivative, mixture or preparation of	
36		such plant, its seeds or extracts.	
37	(31)	Datura stramonium, commonly known as gypsum weed or jimson	
38	()	weed; all parts of the plant presently classified botanically as datura	Į.
39		stramonium, whether growing or not, the seeds thereof, any extract	
40		from any part of such plant, and every compound, manufacture, salt	S.
41		derivative, mixture or preparation of such plant, its seeds or extracts	
42	(32)	N-benzylpiperazine	
43	` '	Some trade or other names: BZP.	

1	(33)	1-(3-[trifluoromethylphenyl])piperazine	
2		Some trade or other names: TFMPP.	
3	(34)	4-Bromo-2,5-dimethoxyphenethylamine	7392
4	(35)	2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), its opt	ical
5		isomers, salts and salts of optical isomers	
6	(36)	Alpha-methyltryptamine (other name: AMT)	7432
7	(37)	5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT), its isome	ers,
8		salts and salts of isomers	
9	(38)	2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E)	7509
10		2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D)	
11	(40)	2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C)	7519
12		2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I)	
13	(42)	2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2)	7385
14	(43)	2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4)	7532
15		2-(2,5-Dimethoxyphenyl)ethanamine (2C-H)	
16	(45)	2-(2,5-Dimethoxy-4-nitrophenyl)ethanamine (2C-N)	7521
17	(46)	2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P)	7524
18	(47)	5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT)	7431
19		Some trade or other names: 5-methoxy-3-[2-(dimethylamino)	
20		ethyl]indole.	
21	(48)	2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-	
22		methoxybenzyl)ethanamine	7538
23		Some trade or other names: 25I–NBOMe; 2C–I–NBOMe; 25I;	
24		Cimbi–5.	
25	(49)	2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine	
26		methoxybenzyl)ethanamine	7537
27		Some trade or other names: 25C-NBOMe; 2C-C-NBOMe; 25C	,
28		Cimbi–82.	
29	(50)	2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-	
30		methoxybenzyl)ethanamine	7536
31		Some trade or other names: 25B–NBOMe; 2C–B–NBOMe; 25B	,
32		Cimbi–36.	
33	(51)	2-(2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine	
34		Some trade or other names: 25H-NBOMe.	
35	(52)	2-(2,5-dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanar	mine
36		Some trade or other names: 25D-NBOMe; 2C-D-NBOMe.	
37	(53)	2-(2,5-dimethoxy-4-nitrophenyl)-N-(2-methoxybenzyl)ethanami	ne
38		Some trade or other names: 25N-NBOMe, 2C-N-NBOMe.	
39		e) Any material, compound, mixture or preparation that contains	
10		tity of the following substances having a depressant effect or	
11		ral nervous system, including its salts, isomers, and salts of iso	
12	wher	never the existence of such salts, isomers, and salts of isome	rs is
13	possi	ible within the specific chemical designation:	

1	(1)	Etizolam
2		Some trade or other names: (4-(2-chlorophenyl)-2-ethyl-9-methyl-
3		6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine)
4	(2)	Mecloqualone2572
5	(3)	Methaqualone2565
6	(4)	Gamma hydroxybutyric acid
7	(f) Unless specifically excepted or unless listed in another schedule,
8	any	material, compound, mixture or preparation that contains any quantity
9		he following substances having a stimulant effect on the central
10	nerv	ous system, including its salts, isomers and salts of isomers:
11	(1)	Aminorex
12		Some other names: Aminoxaphen 2-amino-5-phenyl-2-oxazoline or
13		4,5-dihydro-5-phenyl-2-oxazolamine
14	(2)	Fenethylline
15	(3)	N-ethylamphetamine
16	(4)	(+)cis-4-methylaminorex ((+)cis-4,5-dihydro-4-methyl-5-phenyl-2-
17		oxazolamine)
18	(5)	N,N-dimethylamphetamine (also known as N,N-alpha-trimethyl-
19		benzeneethanamine; N,N-alpha-trimethylphenethylamine)1480
20	(6)	Cathinone (some other names: 2-amino-1-phenol-1-propanone,
21		alpha-amino propiophenone, 2-amino propiophenone and
22		norphedrone)
23	(7)	Substituted cathinones
24		Any compound, except bupropion or compounds listed under a
25		different schedule, structurally derived from 2-aminopropan-1-one
26		by substitution at the 1-position with either phenyl, naphthyl, or
27		thiophene ring systems, whether or not the compound is further
28		modified in any of the following ways:
29		(A) By substitution in the ring system to any extent with alkyl,
30		alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or halide
31		substituents, whether or not further substituted in the ring
32		system by one or more other univalent substituents;
33		(B) by substitution at the 3-position with an acyclic alkyl
34		substituent;
35		(C) by substitution at the 2-amino nitrogen atom with alkyl,
36		dialkyl, benzyl, or methoxybenzyl groups; or
37		(D) by inclusion of the 2-amino nitrogen atom in a cyclic
38	(structure.
39		g) Any material, compound, mixture or preparation that contains any
40 11		ntity of the following substances:
41 42	(1)	N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl), its optical isomers, salts and salts of isomers
+2 13	(2)	N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide
t)	(2)	11-[1-(2-menyi)memyi-4-pipendyi]-11-phenyipiopanamide

 (thenylfentanyl), its optical isomers, salts and salts of isomers

(h) Any of the following cannabinoids, their salts, isomers and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:

- - (A) Industrial hemp, as defined in K.S.A. 2019 Supp. 2-3901, and amendments thereto Any of the following that contains a delta-9 tetrahydrocannabinol concentration of not more than 0.3% on a dry weight basis: All parts of all varieties of the plant Cannabis whether growing or not, the seeds thereof, the resin extracted from any part of the plant and every compound, manufacture, salt, derivative, mixture or preparation of the plant or of the seeds or resin of the plant; or
 - (B) solid waste, as defined in K.S.A. 65-3402, and amendments thereto, and hazardous waste, as defined in K.S.A. 65-3430, and amendments thereto, if such waste is the result of the cultivation, production or processing of industrial hemp, as defined in K.S.A. 2019 Supp. 2-3901, and amendments thereto, and such waste contains a delta-9 tetrahydrocannabinol concentration of not more than 0.3%; or
 - (C) hemp products, as defined in K.S.A. 2019 Supp. 2-3901, and amendments thereto, unless otherwise deemed unlawful pursuant to K.S.A. 2019 Supp. 2-3908, and amendments thereto.
- (2) Naphthoylindoles

Any compound containing a 3-(1-naphthoyl)indole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl) ethyl group, whether or not further substituted in the indole ring to any

extent and whether or not substituted in the benzyl or naphthyl ring to any extent.

(3) Naphthylmethylindoles

3

12

13

14

15

16 17

18

19

20

21 22

23 24

25 26

27

Any compound containing a 1H-indol-3-yl-(1-naphthyl)methane structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the benzyl or naphthyl ring to any extent.

11 (4) Naphthoylpyrroles

Any compound containing a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the pyrrole ring to any extent, whether or not substituted in the benzyl or naphthyl ring to any extent.

(5) Naphthylmethylindenes

Any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indene ring to any extent, whether or not substituted in the benzyl or naphthyl ring to any extent.

(6) Phenylacetylindoles

Any compound containing a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent, whether or not substituted in the benzyl or phenyl ring to any extent.

35 (7) Cyclohexylphenols

Any compound containing a 2-(3-hydroxycyclohexyl)phenol structure with substitution at the 5-position of the phenolic ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not substituted in the cyclohexyl ring to any extent.

42 (8) Benzoylindoles

Any compound containing a 3-(benzoyl)indole structure with

- substitution at the nitrogen atom of the indole ring by an alkyl,
 haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
 benzyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl
 group whether or not further substituted in the indole ring to any
 extent and whether or not substituted in the benzyl or phenyl ring to
 any extent.
- 7 (9) 2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-8 1,4-benzoxazin-6-yl]-1-napthalenylmethanone. 9 Some trade or other names: WIN 55,212-2.
- 10 (10) 9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-11 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol 12 Some trade or other names: HU-210, HU-211.
- 13 (11) Tetramethylcyclopropanoylindoles Any compound containing a 3-tetramethylcyclopropanoylindole 14 structure with substitution at the nitrogen atom of the indole ring by 15 16 an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, 17 cycloalkylethyl, benzyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-18 morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-19 3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in the indole ring to any extent and whether or 20 not substituted in the benzyl or tetramethylcyclopropyl rings to any 21 22 extent
- 23 (12) Indole-3-carboxylate esters 24 Any compound containing a 1H-indole-3-carboxylate ester structure with the ester oxygen bearing a naphthyl, quinolinyl, isoquinolinyl or 25 26 adamantyl group and substitution at the 1 position of the indole ring 27 by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, N-methyl-2-piperidinylmethyl or 2-(4-28 29 morpholinyl)ethyl group, whether or not further substituted on the 30 indole ring to any extent and whether or not substituted on the 31 naphthyl, quinolinyl, isoquinolinyl, adamantyl or benzyl groups to 32 any extent.
- 33 (13) Indazole-3-carboxamides 34 Any compound containing a 1H-indazole-3-carboxamide structure 35 with substitution at the nitrogen of the carboxamide by a naphthyl, quinolinyl, isoquinolinyl, adamantyl, benzyl, 1-amino-1-oxoalkan-2-36 37 yl or 1-alkoxy-1-oxoalkan-2-yl group and substitution at the 1 position of the indazole ring by an alkyl, haloalkyl, cyanoalkyl, 38 alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, N-methyl-2-39 piperidinylmethyl, or 2-(4-morpholinyl)ethyl group, whether or not 40 further substituted on the indazole ring to any extent and whether or 41 42 not substituted on the naphthyl, quinolinyl, isoquinolinyl, adamantyl, 43 1-amino-1-oxoalkan-2-yl, 1-alkoxy-1-oxoalkan-2-yl or benzyl

publication in the Kansas register.

25

1 groups to any extent. 2 (14) Indole-3-carboxamides 3 Any compound containing a 1H-indole-3-carboxamide structure with 4 substitution at the nitrogen of the carboxamide by a naphthyl. 5 quinolinyl, isoquinolinyl, adamantyl, benzyl, 1-amino-1-oxoalkan-2vl or 1-alkoxy-1-oxoalkan-2-vl group and substitution at the 1 6 7 position of the indole ring by an alkyl, haloalkyl, cyanoalkyl, 8 alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, N-methyl-2piperidinylmethyl, or 2-(4-morpholinyl)ethyl group, whether or not 9 further substituted on the indole ring to any extent and whether or not 10 further substituted on the naphthyl, quinolinyl, isoquinolinyl, 11 adamantyl, 1-amino-1-oxoalkan-2-yl, 1-alkoxy-1-oxoalkan-2-yl or 12 13 benzyl groups to any extent. (15) (1H-indazol-3-yl)methanones 14 15 Any compound containing a (1H-indazol-3-vl)methanone structure 16 with the carbonyl carbon bearing a naphthyl group and substitution at 17 the 1 position of the indazole ring by an alkyl, haloalkyl, alkenyl, 18 cycloalkylmethyl, cycloalkylethyl, benzyl, N-methyl-2-19 piperidinylmethyl, or 2-(4-morpholinyl)ethyl group, whether or not 20 further substituted on the indazole ring to any extent and whether or not substituted on the naphthyl or benzyl groups to any extent. 21 22 K.S.A. 2019 Supp. 21-5701, 65-4101 and 65-4105 are hereby 23 repealed. 24 Sec. 5. This act shall take effect and be in force from and after its